Phospho-PTK6 (Y447) Antibody

What is the functional significance of PTK6 Y447 phosphorylation?

Phosphorylation at tyrosine 447 (Y447) serves as a key regulatory mechanism for PTK6 activity. When Y447 becomes phosphorylated, it binds to PTK6's own SH2 domain, inducing an inactive conformation of the protein and inhibiting its kinase activity . This represents an auto-inhibitory mechanism distinct from the activating phosphorylation that occurs at Y342.

The functional significance includes:

• Acts as a molecular switch to turn off PTK6 signaling through intramolecular SH2 domain binding with phosphorylated Y447

• Provides a counterbalance to the activating phosphorylation at Y342, allowing precise regulation of PTK6 activity in cellular contexts

• May be differentially regulated in cancer versus normal tissues, contributing to altered PTK6 signaling in disease states

• Serves as a potential target for therapeutic intervention to modulate PTK6 activity

This phosphorylation site represents a critical node in understanding how PTK6 activity is controlled in both normal and pathological conditions.

How does PTK6 Y447 phosphorylation differ from Y342 phosphorylation in experimental detection?

These two phosphorylation sites represent opposing regulatory mechanisms for PTK6 and require different experimental approaches for proper analysis:

When designing experiments to study PTK6 phosphorylation, researchers should consider using both phospho-specific antibodies to capture the complete regulatory state of the protein. In bacterial expression systems, both sites can undergo autophosphorylation, suggesting an intrinsic regulatory mechanism within the PTK6 protein itself .

What are the recommended applications for Phospho-PTK6 (Y447) antibodies?

Based on validated methods in the literature, Phospho-PTK6 (Y447) antibodies have been successfully employed in several experimental applications:

• Western Blotting (WB): Typically used at dilutions of 1:500-1:2000 . This application provides quantitative assessment of pY447 levels in cell or tissue lysates.

• Immunofluorescence (IF): Recommended dilutions range from 1:200-1:1000 . This allows visualization of subcellular localization of phosphorylated PTK6.

• ELISA: Generally used at higher dilutions (approximately 1:5000) for quantitative measurement in complex samples.

Additional methodological considerations include:

• Sample preparation: For optimal detection, cells may be treated with phosphatase inhibitors during lysis to preserve phosphorylation status .

• Controls: Use of phospho-peptide blocking controls is essential to confirm antibody specificity .

• Stimulation conditions: Treatment with growth factors like EGF (200 ng/ml for 30 minutes) may enhance detection by increasing phosphorylation events .

For accurate interpretation, researchers should consider both the phosphorylation status at Y447 and Y342 to understand the complete regulatory state of PTK6 in their experimental system .

What is the relationship between PTK6 Y447 phosphorylation and cancer progression?

The relationship between PTK6 Y447 phosphorylation and cancer progression is complex and context-dependent:

• Colorectal cancer: PTK6 overexpression correlates with chemoresistance, with aberrant regulation at Y447 potentially contributing to sustained PTK6 activation .

• Prostate cancer: Loss of PTEN (a common event in prostate cancer) leads to increased PTK6 Y342 phosphorylation without affecting Y447, shifting the balance toward activation . This promotes tumorigenesis, with PTK6 activation correlating with poor outcomes in human prostate tumor tissue microarrays .

• Cancer-associated mutations: Specific mutations like P450L (adjacent to Y447) can increase PTK6 autophosphorylation and activity, suggesting that disruption of this regulatory region contributes to oncogenic activation .

Experimental evidence shows that PTK6 Y447 phosphorylation status may serve as a biomarker for tumor aggressiveness and potentially as a therapeutic target, particularly in contexts where PTK6 contributes to chemoresistance mechanisms .

How can I validate the specificity of a Phospho-PTK6 (Y447) antibody in my experimental system?

Rigorous validation of phospho-specific antibodies is critical for reliable research outcomes. For Phospho-PTK6 (Y447) antibodies, implement these validation approaches:

• Phospho-peptide competition assays: Pre-incubate the antibody with the phosphopeptide used as immunogen (typically derived from the region around Y447) . This should abolish specific signal in Western blot or immunofluorescence applications. Several commercial antibodies have been validated using this approach, showing elimination of signal when blocked with phospho-peptide .

• Phosphatase treatment controls: Treat half of your sample with lambda phosphatase to remove phosphorylation. A specific phospho-antibody should show diminished signal in the phosphatase-treated sample.

• PTK6 knockdown/knockout validation: Use siRNA directed against PTK6 (as demonstrated in endothelial cell studies) or CRISPR-based knockout approaches. This should eliminate specific signal from both total and phospho-specific antibodies.

• Mutant expression: Express PTK6 Y447F mutant (where the tyrosine is replaced with phenylalanine) alongside wild-type PTK6. The phospho-Y447 antibody should only detect wild-type protein after appropriate stimulation.

• Stimulus-responsive phosphorylation: Treat cells with stimuli known to affect PTK6 phosphorylation (e.g., EGF treatment has been shown to modulate PTK6 phosphorylation) . Monitor temporal changes in phosphorylation as an indicator of specificity.

A comprehensive validation approach combines multiple methods, with particular attention to controls that distinguish between total PTK6 and specifically phosphorylated forms.

What methodological considerations are important when analyzing PTK6 Y447 phosphorylation in cancer tissues?

When analyzing PTK6 Y447 phosphorylation in cancer tissues, several methodological considerations are critical for accurate data interpretation:

• Sample preservation: Phosphorylation states can be rapidly lost due to phosphatase activity. Use immediate fixation or snap freezing, and include phosphatase inhibitors in all buffer solutions during tissue processing .

• Comparative analysis framework:

  • Always analyze matched tumor and adjacent non-tumor tissues from the same patient

  • Consider parallel assessment of both Y447 and Y342 phosphorylation to understand the activation/inhibition balance

  • Include total PTK6 measurements to normalize phosphorylation levels

• Subcellular localization analysis: PTK6 function differs based on subcellular localization. In prostate tissues, PTK6 shows nuclear localization in normal epithelial cells but cytoplasmic localization in cancer cells . Use confocal microscopy with appropriate markers to assess nuclear versus cytoplasmic distribution of phosphorylated PTK6 .

• Correlation with cancer stage and molecular features: Analyze PTK6 Y447 phosphorylation in the context of:

  • Cancer stage and grade

  • Treatment history (particularly relevant for chemoresistance studies)

  • Status of regulatory proteins like PTEN (which directly impacts PTK6 phosphorylation)

• Technical controls: Include:

  • Phospho-peptide blocking controls

  • Isotype control antibodies

  • Known positive and negative control tissues

These methodological considerations help ensure that observations about PTK6 Y447 phosphorylation accurately reflect the biology of the cancer being studied rather than technical artifacts.

How does the phosphorylation status of PTK6 Y447 change in response to specific cancer treatments?

The dynamics of PTK6 Y447 phosphorylation in response to cancer treatments represent an important but incompletely understood area of research:

• Chemotherapy response: In colorectal cancer (CRC) studies, PTK6 expression is aberrantly overexpressed in tissues undergoing chemotherapy, suggesting altered regulation that may include changes in Y447 phosphorylation status . Experimental evidence from CRC cells treated with 5-FU/L-OHP (standard chemotherapeutic agents) indicates that:

  • PTK6 contributes to chemoresistance mechanisms

  • Small molecule inhibition of PTK6 improved sensitivity to chemotherapy in both nude mouse and patient-derived xenograft (PDX) animal models

• PTEN-targeted therapies: Since PTEN directly dephosphorylates PTK6 at Y342 but not Y447 , therapies targeting the PTEN pathway may alter the balance between activating and inhibitory phosphorylation:

  • MSI-1436, a small molecule inhibitor of PTP1B (another phosphatase that regulates PTK6), promotes PTK6 activation

  • This suggests that phosphatase inhibitors may have unintended consequences on PTK6 signaling that could be monitored via Y447 phosphorylation status

• Growth factor receptor inhibitors: Since PTK6 functions downstream of growth factor receptors including EGFR, ERBB2, and ERBB3 , treatments targeting these receptors likely influence PTK6 phosphorylation:

  • EGF treatment has been shown to modulate PTK6 phosphorylation in experimental systems

  • Monitoring Y447 phosphorylation could provide insights into the efficacy of receptor-targeted therapies

To properly study these dynamics, researchers should employ time-course experiments with appropriate controls and consider the balance between Y342 and Y447 phosphorylation rather than examining either in isolation.

How can I use Phospho-PTK6 (Y447) antibody to study the relationship between PTEN and PTK6 activity?

PTEN and PTK6 have a well-documented regulatory relationship that can be effectively studied using phospho-specific antibodies against both Y342 and Y447:

• Experimental design for PTEN-PTK6 interactions:

  • Use complementary approaches of PTEN overexpression in PTEN-null cell lines and PTEN knockdown in PTEN-positive cells

  • Monitor both PY342 (which is directly dephosphorylated by PTEN) and PY447 (which is not directly affected by PTEN)

  • Compare results in cell lines with different endogenous PTEN status to validate observations

• Critical controls and analytical approaches:

  • Include phosphatase-dead PTEN mutants to distinguish between phosphatase-dependent and adaptor functions of PTEN

  • Use co-immunoprecipitation to assess physical interactions between PTEN and PTK6

  • Employ subcellular fractionation to determine compartment-specific effects, as PTK6 localization affects its function

• Translational relevance in tissue studies:

  • In mouse prostate tissue, conditional disruption of Pten leads to increased phosphorylation of PTK6 Y342, driving tumorigenesis

  • In human prostate tumor tissue microarrays, PTEN loss correlates with increased PTK6 PY342 and poor clinical outcomes

  • Similar analyses could be performed for additional cancer types using Phospho-PTK6 (Y447) antibodies to determine if the regulatory relationship is consistent across different tissues

• Therapeutic implications:

  • Since PTEN selectively dephosphorylates Y342 but not Y447, monitoring both phosphorylation sites could help predict response to PTEN pathway-targeted therapies

  • The efficiency of PTEN-mediated PTK6 dephosphorylation is similar to that of PTP1B, another phosphatase targeting PTK6 , suggesting potential redundancy in regulatory mechanisms

This experimental framework leverages Phospho-PTK6 antibodies to illuminate the nuanced regulatory relationship between tumor suppressor phosphatases and oncogenic kinase activity.

What approaches can be used to study PTK6 Y447 phosphorylation in the context of cancer-associated mutations?

Cancer-associated mutations in PTK6 provide valuable insights into its regulation, with Y447 phosphorylation playing a key role. Several approaches can effectively study this relationship:

• Mutagenesis studies of regulatory regions:

  • Cancer-associated mutations affecting PTK6 regulatory domains have been identified and characterized

  • Mutations in critical regulatory regions (L16F in SH3 domain, R131L in SH2 domain, and P450L adjacent to Y447) significantly increase PTK6 autophosphorylation and kinase activity

  • Site-directed mutagenesis can be used to create these mutations in expression vectors for functional studies, measuring Y447 phosphorylation status as an outcome

• Quantitative analysis of phosphorylation in mutant variants:

  • Express FLAG-tagged wild-type and mutant PTK6 proteins in model cell systems

  • Compare phosphorylation levels using both general phosphotyrosine antibodies and site-specific antibodies for Y342 and Y447

  • Correlate phosphorylation status with functional outcomes using kinase activity assays with synthetic peptide substrates

• Structure-function analysis of the phospho-Y447-SH2 domain interaction:

  • PTK6 SH2 domain has unique features in its loop regions that influence ligand specificity

  • Mutations of conserved residues R85 and H126 disrupt interactions between the SH2 domain and phosphotyrosine-containing peptides

  • These can be used to specifically disrupt the intramolecular regulation by Y447 phosphorylation

• Cancer-specific phenotypic assays:

  • Assess how cancer-associated mutations affecting Y447 phosphorylation impact:

    • Cell proliferation and survival

    • Migration and invasion capabilities

    • Response to chemotherapeutic agents

    • Interactions with other signaling pathways (e.g., JAK2/STAT3)

This multi-faceted approach provides mechanistic understanding of how cancer-associated mutations affect PTK6 regulation through Y447 phosphorylation, with potential implications for targeted therapeutic strategies.

How can I optimize immunofluorescence protocols for Phospho-PTK6 (Y447) detection in different cell types?

Optimizing immunofluorescence protocols for Phospho-PTK6 (Y447) detection requires careful consideration of fixation, permeabilization, and antibody conditions:

• Cell type-specific considerations:

  • For epithelial cells (where PTK6 is commonly expressed): Standard 4% paraformaldehyde fixation works well

  • For endothelial cells: PTK6 localizes to perinuclear and cytosolic regions, requiring gentle permeabilization to preserve these patterns

  • For cancer cell lines: Consider the known subcellular distribution (nuclear in normal prostate epithelium, cytoplasmic in prostate cancer cells)

• Fixation and permeabilization optimization:

  • Test multiple fixation methods (paraformaldehyde vs. methanol) as phospho-epitopes can be sensitive to fixation conditions

  • For membrane-associated PTK6, avoid harsh detergents that might disrupt membrane localization

  • Include phosphatase inhibitors in all buffers to preserve phosphorylation status

• Antibody conditions:

  • Start with recommended dilutions (1:200-1:1000) and optimize for specific cell types

  • Extend primary antibody incubation time (overnight at 4°C) for maximal sensitivity

  • Use phospho-peptide blocking controls to confirm specificity

• Signal enhancement strategies:

  • Consider tyramide signal amplification for low abundance phospho-proteins

  • Use confocal microscopy for optimal subcellular localization assessment

  • Co-stain with markers of specific subcellular compartments to precisely localize phospho-PTK6

• Validation approaches:

  • Compare NIH/3T3 cells with and without EGF treatment (200ng/ml for 30 minutes) as a positive control system

  • Include knockdown/knockout controls to confirm antibody specificity

  • Consider dual staining for total PTK6 and phospho-PTK6 to assess relative phosphorylation levels

These optimization steps will help ensure reproducible and interpretable immunofluorescence results for phospho-PTK6 detection across different experimental systems.

What are the best approaches to quantify changes in PTK6 Y447 phosphorylation in response to experimental manipulations?

Accurate quantification of PTK6 Y447 phosphorylation requires appropriate methodological approaches and controls:

• Western blot quantification:

  • Use titration curves to ensure measurements are within the linear range of detection

  • Always normalize phospho-PTK6 (Y447) to total PTK6 protein levels

  • Include loading controls (β-actin, GAPDH) for total protein normalization

  • Consider using fluorescent secondary antibodies for more accurate quantification

  • Evaluate both Y447 and Y342 phosphorylation to understand the balance between inhibitory and activating phosphorylation

• ELISA-based approaches:

  • Commercial antibodies have been validated for ELISA applications (typically at 1:5000 dilution)

  • Develop sandwich ELISA with capture antibody against total PTK6 and detection antibody against phospho-Y447

  • Include standard curves using recombinant phosphorylated PTK6 for absolute quantification

• Phospho-flow cytometry:

  • Allows single-cell resolution of phosphorylation changes

  • Particularly useful for heterogeneous samples or rare cell populations

  • Requires extensive validation of antibody specificity in flow cytometry applications

• Mass spectrometry approaches:

  • Provides absolute quantification of phosphorylation stoichiometry

  • Can simultaneously measure multiple phosphorylation sites (Y13, Y61, Y66, Y114, Y342, Y447)

  • Requires enrichment strategies (e.g., immunoprecipitation of PTK6 followed by phospho-peptide enrichment)

  • Compare results with antibody-based detection methods for validation

• Temporal dynamics considerations:

  • Design appropriate time-course experiments based on the kinetics of Y447 phosphorylation

  • Evidence suggests Y342 phosphorylation peaks earlier (24 hours) with Y447 phosphorylation increasing at later time points in transfection experiments

  • Include multiple time points when studying responses to stimuli or inhibitors

These approaches provide complementary information about PTK6 Y447 phosphorylation dynamics and should be selected based on specific experimental questions and available resources.

How do different experimental conditions affect the detection of PTK6 Y447 phosphorylation?

Various experimental conditions can significantly impact the detection of PTK6 Y447 phosphorylation, and understanding these factors is crucial for experimental design and interpretation:

• Growth factor stimulation effects:

  • EGF treatment (200ng/ml for 30 minutes) has been shown to modulate PTK6 phosphorylation

  • The hypoxia inducible factors HIF-1α and HIF-2α induce PTK6 transcription , which may subsequently affect phosphorylation levels

  • Estradiol signaling through estrogen receptor-α (ERα) may regulate PTK6, with ERα-positive cell lines showing higher PTK6 protein levels

• Cell density and contact inhibition:

  • PTK6 plays a role in endothelial barrier function, with effects observed in post-confluent cells

  • Consider standardizing cell density for phosphorylation studies, as contact inhibition may affect signaling pathways upstream of PTK6

• Serum starvation considerations:

  • Overnight serum starvation before treatment with TNFα or other stimuli has been used in published protocols

  • This reduces baseline phosphorylation and may enhance detection of treatment-induced changes

• Phosphatase inhibition requirements:

  • Multiple phosphatases regulate PTK6 phosphorylation status, including:

    • Protein tyrosine phosphatase 1B (PTP1B), which negatively regulates PTK6 activity by dephosphorylating Y342

    • PTEN, which directly dephosphorylates PTK6 at Y342 but not Y447

  • Always include phosphatase inhibitors in lysis buffers to preserve phosphorylation status

  • Consider the impact of commonly used phosphatase inhibitors on specific phosphatases known to target PTK6

• Subcellular fractionation effects:

  • PTK6 localization affects its function and possibly its phosphorylation status

  • The long noncoding RNA LINK-A binds PTK6 SH3 and kinase domains, potentially causing conformational changes that promote membrane recruitment

  • Consider separate analysis of nuclear, cytoplasmic, and membrane fractions when studying PTK6 phosphorylation

These considerations highlight the importance of standardized experimental conditions and appropriate controls when studying PTK6 Y447 phosphorylation in different biological contexts.

How can Phospho-PTK6 (Y447) antibodies be used to stratify cancer patients for targeted therapies?

The potential for Phospho-PTK6 (Y447) antibodies in patient stratification is supported by several lines of evidence:

• Prognostic value in tumor tissue analysis:

  • In prostate cancer, PTK6 activation (increased Y342 phosphorylation relative to Y447) correlates with PTEN loss and poor clinical outcomes

  • The balance between inhibitory (Y447) and activating (Y342) phosphorylation may provide more precise prognostic information than total PTK6 levels alone

• Predictive biomarker potential for chemotherapy response:

  • PTK6 overexpression correlates with chemoresistance in colorectal cancer patients

  • Pharmacological targeting of PTK6 using inhibitors enhances chemosensitivity in patient-derived xenograft models

  • Monitoring Y447 phosphorylation status (regulatory site) could identify patients likely to benefit from combined PTK6 inhibition and standard chemotherapy

• Integration with molecular profiling approaches:

  • Combine PTK6 Y447 phosphorylation analysis with:

    • PTEN status assessment (mutational analysis, IHC)

    • Associated signaling pathway activation (JAK2/STAT3)

    • PTK6 mutation screening, particularly in regulatory domains affecting Y447 phosphorylation

• Methodology for clinical application:

  • Immunohistochemistry protocols using phospho-specific antibodies can be standardized for clinical laboratory implementation

  • Quantitative scoring systems should incorporate both staining intensity and subcellular localization

  • Consider multiplexed approaches to simultaneously assess Y447 phosphorylation, Y342 phosphorylation, and total PTK6 levels

• Validation requirements:

  • Retrospective analysis correlating Y447 phosphorylation with treatment response in archival samples

  • Prospective studies in specific cancer types where PTK6 has established roles (colorectal, prostate)

  • Comparison with existing biomarkers to establish incremental value

This approach has particular promise in colorectal cancer, where PTK6 inhibition has been shown to reverse chemoresistance , potentially offering new therapeutic opportunities for patients with poor response to standard treatments.

What is the relationship between PTK6 Y447 phosphorylation and resistance to targeted cancer therapies?

The relationship between PTK6 Y447 phosphorylation and therapeutic resistance involves multiple mechanisms:

• Chemoresistance mechanisms in colorectal cancer:

  • PTK6 is aberrantly overexpressed in clinical CRC tissues undergoing chemotherapy

  • Pharmacological targeting of PTK6 inhibits the JAK2/STAT3 sustained signaling pathway, potentially overcoming resistance mechanisms

  • The balance between inhibitory (Y447) and activating (Y342) phosphorylation may shift during resistance development, favoring the active state

• Interface with growth factor receptor signaling:

  • PTK6 associates with and functions downstream of multiple growth factor receptors (EGFR, ERBB2, ERBB3)

  • These associations may contribute to resistance to receptor-targeted therapies through:

    • Altered phosphorylation of PTK6 at regulatory sites (including Y447)

    • Activation of alternative survival pathways when receptor signaling is blocked

• Pathway redundancy and compensatory mechanisms:

  • PTK6 activates multiple downstream pathways including:

    • STAT3 and STAT5B to promote proliferation

    • AKT signaling to enhance survival

    • RhoA/Rac1 pathways affecting migration and invasion

  • Reduced Y447 phosphorylation (removing auto-inhibition) could compensate for therapeutic inhibition of these downstream pathways

• Experimental evidence from model systems:

  • In mouse models and PDX models, small molecule PTK6 inhibitor XMU-MP-2 improved sensitivity to standard chemotherapeutics (5-FU/L-OHP)

  • This suggests that altered PTK6 regulation (potentially including Y447 phosphorylation) contributes to therapeutic resistance

• Clinical correlations and potential interventions:

  • Monitoring changes in Y447 phosphorylation before and after therapy could identify developing resistance

  • Patients showing decreased Y447 phosphorylation (indicating reduced auto-inhibition) might benefit from combination approaches including PTK6 inhibitors

Understanding this relationship could inform more effective combination therapy strategies and help identify patients at risk of developing resistance to standard treatments.

How might novel PTK6 inhibitors differentially affect Y447 versus Y342 phosphorylation status?

The development of novel PTK6 inhibitors presents an opportunity to understand the complex regulation of this kinase through differential effects on its phosphorylation sites:

• Mechanistic classification of inhibitor types:

  • ATP-competitive inhibitors may prevent autophosphorylation at both Y342 and Y447

  • Allosteric inhibitors might differentially affect these sites based on their mechanism

  • Inhibitors targeting the SH3 or SH2 domains could specifically disrupt regulatory interactions involving Y447 phosphorylation

• Experimental assessment approaches:

  • Time-course analysis of Y447 and Y342 phosphorylation following inhibitor treatment

  • Dose-response studies to identify differential sensitivity of each phosphorylation site

  • Combination with phosphatase inhibitors to determine if the effects are due to altered phosphorylation or enhanced dephosphorylation

• Current evidence from model compounds:

  • The small molecule inhibitor XMU-MP-2 has shown efficacy in enhancing chemosensitivity in colorectal cancer models

  • Analyzing the specific effects of this compound on Y447 versus Y342 phosphorylation could provide insights into its mechanism of action

• Structure-activity relationships:

  • Correlate chemical structures of various PTK6 inhibitors with their differential effects on Y447 and Y342 phosphorylation

  • Use this information to design inhibitors with specific effects on the regulatory versus activating phosphorylation sites

• Biological consequences of differential inhibition:

  • Y447 phosphorylation affects intramolecular SH2 domain binding and auto-inhibition

  • Y342 phosphorylation directly increases kinase activity

  • Inhibitors specifically affecting one site could have distinct biological consequences and therapeutic applications

This research direction could lead to more selective therapeutic approaches targeting PTK6 in cancer, with potential for reduced off-target effects and enhanced efficacy.

What is the potential role of PTK6 Y447 phosphorylation in immune cell function and cancer immunotherapy response?

The role of PTK6 in immune cell function represents an emerging area with implications for cancer immunotherapy:

• PTK6 expression in immune and endothelial cells:

  • PTK6 is expressed in endothelial cells and contributes to vascular endothelial hyperpermeability in response to TNFα

  • This suggests potential roles in tumor microenvironment regulation and immune cell trafficking

• Barrier function and immune cell infiltration:

  • PTK6 knockdown rescued TNFα-mediated endothelial barrier dysfunction by approximately 75%

  • This could affect immune cell infiltration into tumors, potentially influencing immunotherapy response

  • Y447 phosphorylation status may regulate this function, though this remains to be directly tested

• Cytokine signaling interface:

  • PTK6 is linked to JAK2/STAT3 signaling pathways , which are critical in immune cell function

  • Proinflammatory cytokines TNFα/INFγ cause barrier dysfunction that PTK6 may influence

  • The balance between Y447 (inhibitory) and Y342 (activating) phosphorylation could modulate these effects

• Potential research approaches:

  • Analyze PTK6 Y447 phosphorylation in tumor-associated endothelial cells and tumor-infiltrating immune cells

  • Correlate phosphorylation patterns with immunotherapy response in preclinical models

  • Determine if PTK6 inhibitors affect immune cell recruitment or function in the tumor microenvironment

• Therapeutic implications:

  • Combined targeting of PTK6 might enhance immunotherapy efficacy by:

    • Improving immune cell infiltration through effects on endothelial barrier function

    • Modulating cytokine signaling within the tumor microenvironment

    • Directly affecting immune cell function through pathways like JAK2/STAT3